To put it in a nutshell, neoadjuvant chemotherapy combined with laparoscopic surgery offers a variety of advantages in the treatment of patients with middle and low rectal cancer, such as short operation time, less blood loss, high success rate, rapid recovery, low recurrence rate, significantly reduced VEGF levels, and better prognosis than those who underwent surgery directly. The gene discussed is VEGFA; the disease is rectal cancer.